SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Arcadis N.V. (ARCAY) trades at a trailing P/E of 11.6, forward P/E of 9.0. Trailing earnings yield is 8.62%, forward earnings yield 11.14%. PEG 0.31 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (11.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.31); earnings yield beats bond yields (8.62%).
- Forward P/E 9.0 (down from trailing 11.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.31 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 8.62% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 11.14% as earnings recover.
Overall SharesGrow Score: 69/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARCAY
Valuation Multiples
P/E (TTM)11.6
Forward P/E9.0
PEG Ratio0.31
Forward PEG0.31
P/B Ratio0.00
P/S Ratio0.49
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.33
Forward EPS (Est.)$3.01
Book Value / Share$0.00
Revenue / Share$54.71
FCF / Share$0.00
Yields & Fair Value
Earnings Yield8.62%
Forward Earnings Yield11.14%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.74 |
$3.33B |
$64.15M |
1.9% |
| 2017 |
$0.78 |
$3.22B |
$70.8M |
2.2% |
| 2018 |
$-0.31 |
$3.26B |
$-26.7M |
-0.8% |
| 2019 |
$0.14 |
$3.47B |
$12.3M |
0.4% |
| 2020 |
$0.21 |
$3.3B |
$18.88M |
0.6% |
| 2021 |
$1.87 |
$3.38B |
$167.88M |
5% |
| 2022 |
$1.47 |
$4.03B |
$131.52M |
3.3% |
| 2023 |
$1.78 |
$5B |
$159.98M |
3.2% |
| 2024 |
$2.71 |
$5B |
$243M |
4.9% |
| 2025 |
$2.33 |
$4.88B |
$208M |
4.3% |
